
    
      Study OXN3508 is a multicenter double-blind, double-dummy, randomised, cross-over, 2-period,
      phase III study in male and female subjects with severe non-malignant or malignant pain that
      requires around-the-clock opioid therapy at a daily dose of 120/60 mg or 160/80 mg
      oxycodone/naloxone prolonged release (OXN PR).
    
  